The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s (LLY) weight-loss pill for commercial sales, sending the company’s stock up 4% in midday trading on April 1.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eli Lilly said the once-daily pill will be sold under the name “Foundayo.” The pharmaceutical company plans to start shipping the obesity medication from direct-to-consumer platform LillyDirect on April 6. It will be available at retail pharmacies and on telehealth platforms by mid-April, added Eli Lilly.
People with insurance coverage could pay as little as $25 for a one-month supply of the weight-loss pill, while people paying out of pocket are likely to pay between $149 and $349 per month, depending on the medication’s dosage.
Early FDA Approval
The FDA approval of Eli Lilly’s weight-loss pill comes a few weeks earlier than expected. Most analysts expected the approval to come by mid-April. Eli Lilly had applied to the FDA for approval of its weight-loss pill as part of a speedy review process reserved for medications deemed to be a national priority.
Eli Lilly’s weight-loss pill Foundayo comes to market about three months after archrival Novo Nordisk’s (NVO) Wegovy weight-loss pill, setting the stage for the next battle between the rival obesity drug makers that are at the forefront of GLP-1 medications.
The April 1 FDA approval means that sales of the new weight-loss pill will be included in Eli Lilly’s second-quarter 2026 financial results.
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Strong Buy rating among 19 Wall Street analysts. That rating is based on 16 Buy, two Hold, and one Sell recommendations issued in the last three months. The average LLY price target of $1,247.38 implies 31.53% upside from current levels.
